Diseases and Conditions

The nonclinical drug candidates that Akros Pharma takes into clinical development come out of the research conducted by the Central Pharmaceutical Research Institute (CPRI) of JT Pharmaceuticals in Osaka, Japan. The current development focus for Akros reflects the research focus at CPRI.

Currently, CPRI and Akros are working to develop new therapeutics for the following disease states:




Code (Generic Name)





Potential Indication





Dosage form





Mechanism





Stage


JTE-051
  • Autoimmune diseases
  • Allergic diseases
OralInterleukin-2 inducible T cell kinase inhibitorSuppresses overactive immune response via inhibition of the signal to activate T cells related to immune response.Phase2
JTT-251
  • Type 2 diabetes mellitus
OralPDHK inhibitorDecreases blood glucose by activation of pyruvate dehydrogenase (PDH) related to carbohydrate metabolism.Phase1
JTT-662
  • Type 2 diabetes mellitus
OralSGLT1 inhibitorSuppresses postprandial hyperglycemia and normalizes blood glucose level via inhibition of SGLT1Phase1
JTT-861
  • Chronic heart failure
OralPDHK inhibitorImproves cardiac function by activation of pyruvate dehydrogenase (PDH) related to carbohydrate metabolism.Phase1

Clinical trial phase presented above is based on the first dose.